Executive Summary
CMS reopened the National Coverage Determination for TAVR (CAG-00430R2), sending Edwards to a 52-week high on expectations of broader access, even as the clinical foundation looks shakier than the market reaction implies. A single-center LFSAS cohort in American Journal of Cardiology found post-TAVR flow normalization did not independently predict 1-year survival (adjusted HR 0.82, 95% CI 0.51–1.30), undercutting a long-held physiologic assumption used to justify TAVR in low-flow phenotypes. A separate machine-learning study reported a 26% reduction in pacemaker implantation with algorithmic valve selection, exposing how much of current THV prescription is empirical rather than evidence-based — which tightens the case for protocolized, anatomy-driven valve choice and complicates any rush to expand TAVR coverage further.
- nnU-Net deep learning quantified aortic valve calcium against gravimetric ground truth (r=0.967), outperforming the 450-HU threshold and supporting 850 HU as the preferred fixed cutoff (BMC Cardiovasc Disord).
- A data-driven THV prescription model cut predicted PPI rates 26% (US) and 16% (Greek validation) versus current operator choice (Health Care Manag Sci).
- Edwards Lifesciences hit a 52-week high after CMS proposed broader Medicare TAVR coverage (MSN).
- Edwards' transcatheter tricuspid program used discrete-choice patient-preference data to inform pivotal trial and FDA submission design (Ther Innov Regul Sci).
- Mumbai reported a 25% YoY rise in TAVI and minimally invasive cardiac procedures, signaling continued ex-US volume growth (TheWire.in).
What to watch: the CMS NCD comment period for CAG-00430R2 and Edwards' Q2 print on July 23 will set the tone for whether the market's coverage-expansion thesis survives the next durability data drop.
Aortic Valve (TAVR/TAVI)
The flow-state dogma in low-flow severe AS just took a hit. A single-center retrospective of 567 LFSAS patients (SVi ≤35 mL/m²) treated 2019–2022 found post-TAVR stroke volume normalization was not independently associated with the 1-year composite of death or HF hospitalization (13.8% vs 17.4%; adjusted HR 0.82, 95% CI 0.51–1.30, p=0.40), with no interaction by balloon-expandable vs self-expanding valve (Pint=0.31). Underlying myocardial and systemic biology drive prognosis more than procedural hemodynamics — a useful corrective to the idea that fixing the gradient reliably fixes the patient. Limitations are real: single quaternary center, retrospective, no surgical comparator arm. ESC 2025 and ACC/AHA 2020 both recommend TAVR as Class I for symptomatic LFSAS with reduced LVEF, but neither guideline ties post-procedural flow recovery to outcomes as a discrete endpoint — today's data suggest that assumption should not be imported silently into clinical decision-making.
[NOTABLE] A separate ML study built a leaf-level prescriptive model for THV selection across US and Greek cohorts and reported a 26% relative reduction in PPI versus current standard of care (16% in external validation). ACC/AHA 2020 and ESC 2025 provide no operator-level direction on balloon-expandable vs self-expanding valve choice; this fills a real gap, though prospective validation is required before adoption. SAVR remains Class I under ESC 2025 for patients under 70 with low surgical risk (STS-PROM + EuroSCORE II <4%), and the OCEAN-TAVI 7-year signal in women with small annuli — referenced in today's JACC Asia commentary — keeps the durability question open, particularly where surgical root enlargement avoids prosthesis–patient mismatch.
Mitral Valve
No primary mitral data today. The standing context: ESC 2025 elevated TEER for ventricular secondary MR to Class I (LOE A) on the strength of COAPT, RESHAPE-HF2, and pooled meta-analysis, while ACC/AHA 2020 holds at Class IIa. That gap is the single largest transatlantic disagreement in mitral practice and is where the next round of US guideline revision will concentrate.
Tricuspid Valve
Edwards' transcatheter tricuspid valve replacement program features in a cross-industry review of patient-preference information (PPI) use in device development. Discrete-choice experiments informed pivotal trial design and FDA submission strategy for the EVOQUE system, alongside CVRx, Medtronic, J&J, and Abbott case studies. The methodologic point is not trivial: TR is a symptom-and-QoL disease across much of its severe spectrum, and TRILUMINATE Pivotal and TRISCEND II were driven largely by patient-reported outcomes. ESC 2025 made transcatheter TV treatment Class IIa (LOE A) for high-risk symptomatic severe TR without severe RV dysfunction — a category that did not exist in ACC/AHA 2020. Isolated TV surgery historically carried 8–20% mortality; ESC 2025 still recommends surgery (Class I) for symptomatic severe primary TR when the patient is operable, with the explicit caveat that referral has historically come too late. The PPI methodology does not change the clinical evidence base, but it explains why FDA labels for tricuspid devices are written around symptom burden and QoL rather than mortality.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. A methodological critique in General Thoracic and Cardiovascular Surgery targeted a recently published isolated-SAVR survival prediction model in the TAVR era, questioning the model's methodologic assumptions. As TAVR penetrates lower-risk and younger populations, the SAVR cohort becomes increasingly selected, which biases every retrospective comparison. Any survival model built on contemporary SAVR registries must grapple with that selection effect — and ESC 2025 risk stratification (STS-PROM + EuroSCORE II <4% for SAVR preference under age 70) depends on those models being calibrated correctly.
Device & Technology
Aortic valve calcium quantification on contrast-enhanced CT now has a physical-truth benchmark. Against gravimetric calcium weight from 50 surgically explanted leaflets (ashed at 550°C, 12h), an nnU-Net deep learning segmentation achieved Pearson r=0.967, bias +6.2 mg, RMSE 13.7 mg, with Dice 0.873. The 450-HU fixed threshold showed significant proportional bias (p=0.024) and substantially worse RMSE (42.1 mg); 850 HU performed materially better and is now the supported fixed-threshold default. This is the first validation against an absolute physical reference rather than non-contrast Agatston — a meaningful step up. Practical implication for TAVR planning: centers still using 450 HU on contrast studies for low-flow low-gradient confirmation are systematically overestimating calcium, and the bias is non-uniform. ESC 2025 and ACC/AHA 2020 both endorse CT calcium scoring for LFLG confirmation (male threshold >2000 AU, female >1200 AU on non-contrast Agatston); the 850-HU finding is directly relevant where non-contrast acquisition is unavailable.
Regulatory & Policy
CMS reopened the TAVR NCD under CAG-00430R2, signaling intent to revisit volume thresholds, two-surgeon requirements, and heart-team composition. Reaction across the cardiology community has been mixed: relaxing site requirements expands access but risks diluting outcomes data in lower-volume programs. The two-surgeon rule has been the most contentious; surgical societies will weigh in heavily during comment.
Industry & Market
Volume growth is real and global. Mumbai reported a 25% YoY rise in TAVI and minimally invasive cardiac procedures, consistent with the broader pattern of TAVR adoption running ahead of long-term durability data — particularly in markets where mechanical valves and SAVR remain dominant in younger patients. ESC Cardio-Oncology 2026 highlighted TAVI in cancer patients as an expanding niche; this is a population where surgical risk is genuinely elevated and TAVR's case is strongest.
Financial Analysis
Edwards is the clear winner on today's regulatory news, hitting a 52-week high on the CMS coverage proposal. The thesis is straightforward: relaxed site requirements expand the addressable footprint for SAPIEN, and Edwards' transcatheter tricuspid pipeline (EVOQUE) is well-positioned with both an ESC Class IIa recommendation and an FDA label backed by formal patient-preference data. The clinical-evidence counterweight: today's LFSAS flow-state paper and the ML PPI study both show patient-level outcome heterogeneity is larger than current valve-selection practice acknowledges. Neither finding hits revenue in 2026, but both should temper any narrative that TAVR is a fully de-risked franchise. Medtronic and Abbott both sit well below 6-month highs on broader sector concerns; Boston Scientific has lost half its value over six months despite a strong-buy consensus, reflecting concerns largely unrelated to its structural heart business.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $87.36, +0.78% on the day, +1.98% over 6 months — at the top of its 52-week range ($72.30–$89.60).
- Market cap $50.3B; trailing P/E 47.22, forward P/E 25.94; beta 0.87.
- Analyst target $96.92 (range $84–$110, 26 analysts); consensus buy.
- Next earnings July 23, 2026 (EPS est $0.74, revenue est $1.70B).
- Trading near highs on the CMS NCD reopening; tricuspid program validated by today's PPI cross-industry review. Watch Q2 print for tricuspid contribution.
Medtronic (MDT)
- Close $79.34, +1.54% on the day, -18.30% over 6 months.
- Market cap $101.6B; trailing P/E 21.27, forward P/E 12.38; beta 0.60.
- Analyst target $98 (range $78–$121, 26 analysts); consensus buy.
- Next earnings August 18, 2026 (EPS est $1.39, revenue est $9.55B).
- Evolut franchise faces fresh evidence that valve selection is operator-dependent — the ML prescription paper today (PMID 42322448) may pressure both Evolut and SAPIEN choice rationales.
Abbott (ABT)
- Close $88.41, -0.10% on the day, -28.72% over 6 months.
- Market cap $154.0B; trailing P/E 24.76, forward P/E 14.59; beta 0.62.
- Analyst target $116.54 (range $92–$135, 24 analysts); consensus buy.
- Next earnings July 16, 2026 (EPS est $1.28, revenue est $12.53B).
- TriClip remains the established TR TEER incumbent, but transcatheter TV replacement (EVOQUE) is gaining label and pivotal-trial momentum on QoL endpoints.
Boston Scientific (BSX)
- Close $45.29, +0.76% on the day, -52.63% over 6 months.
- Market cap $67.3B; trailing P/E 18.95, forward P/E 12.16; beta 0.56.
- Analyst target $76.48 (range $55–$106, 29 analysts); consensus strong buy.
- Next earnings July 29, 2026 (EPS est $0.83, revenue est $5.37B).
- Heavy 6-month drawdown reflects broader portfolio concerns; structural heart (ACURATE, Sentinel) is a smaller piece of the story than Watchman and EP.
Anteris Technologies (AVR.AX)
- Close A$13.88, +4.20% on the day, +95.49% over 6 months — near 52-week high.
- Market cap A$1.4B; forward P/E -6.37 (pre-revenue); beta 0.73.
- Single-analyst target A$13.00; no aggregated recommendation.
- DurAVR THV continues to attract speculative interest; clinical evidence remains early-stage. Best treated as a thesis stock until pivotal data lands.
The day's CMS proposal and Edwards' run to a 52-week high mask a more interesting clinical picture — patient-level outcome heterogeneity (the LFSAS data) and operator-level selection variability (the ML study) together suggest the next phase of TAVR maturation will be less about expanding indications and more about refining who gets which valve. That's an Edwards strength but not exclusively. Watch Q2 prints for guidance on tricuspid contribution and any commentary on CMS proposal modeling.
Clinical Trial Updates
Private-company watch: JenaValve, J Valve Technology, and Meril Life Sciences continue to advance non-public pipelines. JenaValve's Trilogy received CE mark for aortic regurgitation — directly relevant to ESC 2025's new Class IIb recommendation for TAVI in inoperable AR, an area where SAVR has been the only substantive option for decades.
Next: the CMS NCD comment window will produce the highest-signal regulatory commentary of the quarter, and the OCEAN-TAVI 7-year data referenced in today's JACC Asia note remain the most important durability readout still pending for the small-annulus female cohort — where the SAVR-vs-TAVR durability question is sharpest.